{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:22:46Z","timestamp":1788960166829,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01968-8","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:52:16Z","timestamp":1740178336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD"],"prefix":"10.1007","volume":"16","author":[{"given":"Jing","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruinan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"3","key":"1968_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","volume":"112","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Schwartz S, Bartram CR, et al. Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918\u20139.","journal-title":"Blood"},{"issue":"14","key":"1968_CR2","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548\u201359.","journal-title":"Blood"},{"issue":"12","key":"1968_CR3","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788\u2013801.","journal-title":"Cancer"},{"issue":"3","key":"1968_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547\u201361.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1968_CR5","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","volume":"7","author":"R Bassan","year":"2023","unstructured":"Bassan R, Chiaretti S, Della Starza I, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;7(16):4448\u201361.","journal-title":"Blood Adv"},{"issue":"8","key":"1968_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/cncr.23819","volume":"113","author":"S O'Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097\u2013101.","journal-title":"Cancer"},{"issue":"4","key":"1968_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","volume":"157","author":"JI Sive","year":"2012","unstructured":"Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol. 2012;157(4):463\u201371.","journal-title":"Br J Haematol"},{"issue":"14","key":"1968_CR8","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2217\/fon.14.81","volume":"10","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Litzow MR. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. Future Oncol. 2014;10(14):2201\u201312.","journal-title":"Future Oncol"},{"issue":"9","key":"1968_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"14","key":"1968_CR10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522\u201331.","journal-title":"Blood"},{"issue":"4","key":"1968_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1968_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2023-180472","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. Blood. 2023;142(Supplement 1):964\u2013964.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1968_CR13","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1182\/blood-2022-156080","volume":"140","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Aldoss I, Fleming S, et al. Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled golden gate study. Blood. 2022;140(Supplement 1):6134\u20136.","journal-title":"Blood"},{"issue":"1","key":"1968_CR14","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1182\/blood-2022-157361","volume":"140","author":"C Salek","year":"2022","unstructured":"Salek C, Folber F, Hrabovsky S, et al. Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. primary endpoint analysis of the blina-cell trial. Blood. 2022;140(1):3258\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1968_CR15","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2021-151826","volume":"138","author":"S Fleming","year":"2021","unstructured":"Fleming S, Reynolds J, Bajel A, et al. Sequential blinatumomab with reduced intensity chemotherapy in the treatment of older adults with newly diagnosed Ph negative B-precursor acute lymphoblastic leukemia - interim analysis of the australasian leukemia and lymphoma group ALL08 Study. Blood. 2021;138(Supplement 1):1234\u20131234.","journal-title":"Blood"},{"issue":"9","key":"1968_CR16","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","volume":"107","author":"A Cabannes-Hamy","year":"2022","unstructured":"Cabannes-Hamy A, Brissot E, Leguay T, et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. 2022;107(9):2072\u201380.","journal-title":"Haematologica"},{"issue":"4","key":"1968_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137(4):471\u201384.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1968_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2023-186998","volume":"142","author":"A Laqua","year":"2023","unstructured":"Laqua A, Raifer H, Kelm M, et al. In-depth immune profiling in children with BCP-ALL within the AIEOP-BFM ALL 2017 study. Blood. 2023;142(Supplement 1):595\u2013595.","journal-title":"Blood"},{"issue":"1","key":"1968_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","volume":"17","author":"J Lu","year":"2024","unstructured":"Lu J, Qiu H, Wang Y, et al. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J Hematol Oncol. 2024;17(1):79. https:\/\/doi.org\/10.1186\/s13045-024-01597-8.","journal-title":"J Hematol Oncol"},{"key":"1968_CR20","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u20132405. Blood. 2016.128(3):462\u2013463.","DOI":"10.1182\/blood-2016-06-721662"},{"key":"1968_CR21","unstructured":"(NCCN) NCCN. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia, Version 3.2023. 2023."},{"issue":"6","key":"1968_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.leukres.2007.10.019","volume":"32","author":"W Xu","year":"2008","unstructured":"Xu W, Li JY, Qian SX, et al. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia. Leuk Res. 2008;32(6):930\u20135.","journal-title":"Leuk Res"},{"key":"1968_CR23","unstructured":"U.S. Department of health and human services NIoH, National cancer institute. common terminology criteria for adverse events (CTCAE) Version 5.0. 2017."},{"issue":"12","key":"1968_CR24","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","volume":"101","author":"MB Vidriales","year":"2003","unstructured":"Vidriales MB, P\u00e9rez JJ, L\u00f3pez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101(12):4695\u2013700.","journal-title":"Blood"},{"issue":"5","key":"1968_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532\u201343.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1968_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843\u201354.","journal-title":"JAMA"},{"issue":"18","key":"1968_CR27","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"1968_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/01.HS9.0000844352.62588.a4","volume":"6","author":"A Rijneveld","year":"2022","unstructured":"Rijneveld A, Gradowska P, Bellido M, et al. P366: blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-all in adults a phase II hovon trial. HemaSphere. 2022;6:266\u20137.","journal-title":"HemaSphere"},{"issue":"5","key":"1968_CR29","first-page":"1556","volume":"92","author":"RA Larson","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556\u201364.","journal-title":"Blood"},{"issue":"8","key":"1968_CR30","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025\u201337.","journal-title":"Blood"},{"issue":"12","key":"1968_CR31","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878\u201385.","journal-title":"Lancet Haematol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01968-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:52:22Z","timestamp":1740178342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01968-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01968-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study comprised both prospective and retrospective components. The prospective part was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Soochow University (Approval Number: 2022235). Ethical approval for the retrospective part was waived by the local Ethics Committee of the First Affiliated Hospital of Soochow University, considering the retrospective nature of the study and that all procedures performed were part of routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients or their legal guardians for the prospective part of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"223"}}